Refine
Document Type
- Article (5) (remove)
Language
- English (5)
Has Fulltext
- yes (5)
Is part of the Bibliography
- no (5)
Keywords
- Postoperative radiochemotherapy (2)
- Biomarker (1)
- CXCR4 (1)
- DKTK-ROG (1)
- HNSCC (1)
- HPV (1)
- Head and neck cancer (1)
- Hsp70 (1)
- IHC (1)
- KIF (1)
- KIF11 (1)
- NCH93 (1)
- NK cells (1)
- Prognostic (1)
- SCCHN (1)
- SDF-1 (1)
- gene signature (1)
- head and neck squamous cell carcinoma (1)
- kinesin (1)
- meningioma (1)
- p16 (1)
- p53 (1)
- postoperative radiochemotherapy (1)
- postoperative radiotherapy (1)
- prognostic biomarker (1)
- propensity score matching (1)
- retrospective trial (1)
Institute
- Medizin (5)
Objective: To investigate the impact of HPV status in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received surgery and cisplatin-based postoperative radiochemotherapy.
Materials and methods: For 221 patients with locally advanced squamous cell carcinoma of the hypopharynx, oropharynx or oral cavity treated at the 8 partner sites of the German Cancer Consortium, the impact of HPV DNA, p16 overexpression and p53 expression on outcome were retrospectively analysed. The primary endpoint was loco-regional tumour control; secondary endpoints were distant metastases and overall survival.
Results: In the total patient population, univariate analyses revealed a significant impact of HPV16 DNA positivity, p16 overexpression, p53 positivity and tumour site on loco-regional tumour control. Multivariate analysis stratified for tumour site showed that positive HPV 16 DNA status correlated with loco-regional tumour control in patients with oropharyngeal carcinoma (p = 0.02) but not in the oral cavity carcinoma group. Multivariate evaluation of the secondary endpoints in the total population revealed a significant association of HPV16 DNA positivity with overall survival (p < 0.01) but not with distant metastases.
Conclusions: HPV16 DNA status appears to be a strong prognosticator of loco-regional tumour control after postoperative cisplatin-based radiochemotherapy of locally advanced oropharyngeal carcinoma and is now being explored in a prospective validation trial.